It has been shown that CXCL12 can help to distinguish between benign lesions and PCa among patients presenting with low serum PSA [20], which prompted us to evaluate mCXCL12 with respect to the initial serum PSA in the full cohort of patients. This evidence concerns the gene CXCL12 and posterior cortical atrophy.